R-SABE and ABEL versus Blood Volume [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2015-08-11 18:41 (3475 d 11:31 ago) – Posting: # 15232
Views: 5,191

Hi Lucas,

yep, combos can be challenging when it comes to the blood volume. What I have seen is to optimize the sampling schedule for each drug and split samples accordingly. Drawbacks:

❝ is it possible to not use the replicated samples for the other 2 drugs and apply conventional ABE for them, and consider the replication only for the HVD?


Not sure whether I understand you. Can you post sequences / periods you have in mind?

❝ Other option would be to use Balaam's 4x2 design, but I don't think that someone has budget for that... :-D


Correct. In Balaam’s design we throw away half of the sample size in the estimation of T/R. Furthermore, I don’t know how to estimate the sample size. RT|TR|RR|TT is currently not implemented in PowerTOST sampleN.scABEL().

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,380 posts in 4,914 threads, 1,665 registered users;
74 visitors (0 registered, 74 guests [including 10 identified bots]).
Forum time: 05:12 CET (Europe/Vienna)

When people learn no tools of judgment
and merely follow their hopes,
the seeds of political manipulation are sown.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5